Azenta Inc (NAS:AZTA)
$ 51.3 -0.27 (-0.52%) Market Cap: 2.34 Bil Enterprise Value: 1.94 Bil PE Ratio: 0 PB Ratio: 1.32 GF Score: 73/100

Azenta Inc at UBS Genomics 2.0 and MedTech Innovations Summit Transcript

Aug 15, 2023 / 10:00PM GMT
Release Date Price: $56.97 (+1.61%)
John Newton Sourbeer
UBS Investment Bank, Research Division - Equity Research Associate

Great. For our next panel here, we're going to do a presentation with Azenta. They're going to be diving into some of their genomics business. And representing Azenta today, we have Sara Silverman, who is Head of IR; and Andrea O'Hara, who is a technical specialist within the genomics business.

So Sara, I'll let you go ahead and get started here.

Sara Silverman
Azenta, Inc. - Head of IR & Corporate Communications

Okay. Great. Thanks, John. It's really great to be here at the UBS conference. We've had a great day of meetings, and we're really excited about this presentation we're about to do. So we're going to do an overview of the business as we typically do, but we're going to do something extra, a little special today. We have Andrea here, and she's going to do a deep dive into our genomics business.

I get the question a lot from investors, from analysts. They say, what about your genomics business is differentiated? How do you support the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot